COVID-19 and Cancer Patients: What You Should Know

COVID-19 and Cancer Patients: What You Should Know

The Facebook live event, COVID-19 and Cancer Patients: What You Should Know, was hosted by Massive Bio on January 13, 2021. The live event featured interviews about COVID-19 and its effect on cancer patients from Massive Bio medical experts. Guests included Massive Bio’s Co-founder and Chief Medical Advisor, Dr. Arturo Loaiza-Bonilla, MD; Chief Nursing Officer, Kristin Johnston, BSN, RN; and host Chief Customer Delivery Manager, Stephanie Tran.

Massive Bio is tackling the inefficiencies of clinical trials during the COVID-19 pandemic for cancer patients and their physicians. Our AI-precision technology will pre-screen your unique profile over 125 different parameters to make sure you are eligible before you need to travel to visit the trial site. Paired with modern technology, our dedicated team of patient advocates help to make sure all your patient needs are met during the cancer journey, saving you time and reducing your exposure to viral infection.

Topics covered include:

Enrolling in clinical trials during the COVID-19 pandemic
COVID-19 vaccine
Virtual Cancer Care Services
If you are looking for information about how COVID-19 effects cancer patients in life, treatment, clinical trials, diagnosis and more, Read more “COVID-19 and Cancer Patients: What You Should Know”

Advanced Non-Small Cell Lung Cancer

• Fast Facts
• Hopeful Highlights

1. NSCLC accounts for about 85% of all lung cancers
2. There are 3 types of NSCLC: Squamous cell carcinoma, adenocarcinoma, and large cell carcinoma.
3. The 3 most common symptoms are shortness of breath, a worsening cough, or coughing up blood.
4. Smoking is one of the greatest, controllable risk factors for lung cancer. As smoking has decreased in the United States, so have the diagnoses of lung cancer.
5. Kentucky has the highest incidence of lung cancer while Utah has the lowest.

1. The addition of palliative care (pain management, social services, spiritual advisement, etc) to standard chemotherapy has been shown to improve the survival rate for advanced lung cancer!
2. The first ever targeted drug for NSCLC was approved in 2003, opening the door for multiple new and innovative treatments such as anti-angiogenic drugs in 2005 and three different immunotherapies in 2015.
3. New early detection tests are being developed such as spiral CT scans and sputum sample testing that can detect cancer earlier in people at high risk for the disease.

More Details: NSCLC Advanced Clinical Trials

Read More

Lung Cancer Mutations

Read More

Non-Small Cell Lung Cancer Genetic Markers

Read More

Lung Cancer Screening Guidelines

Read More

Biomarkers in Non-Small Cell Lung Cancer

Read More

Are Clinical Trials an Option For Me?

If standard treatment options have failed, then yes. Many promising new drugs have been developed over the last decade, but it will be years until they can be prescribed in clinics. So, clinical trials are the safest setting to use these drugs, and we can help you find and choose the most promising ones. Read more “Are Clinical Trials an Option For Me?”

Smoking and Cancer

Read More